Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Tancevski, I; Demetz, E; Eller, P.
Sobetirome: a selective thyromimetic for the treatment of dyslipidemia.
Recent Pat Cardiovasc Drug Discov. 2011; 6(1):16-19 Doi: 10.2174/157489011794578473
PubMed FullText FullText_MUG

 

Co-Autor*innen der Med Uni Graz
Eller Philipp
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
Atherosclerosis and its clinical sequelae still represent the primary cause of death in Western societies. During the past 25 years, a novel drug class to treat dyslipidemia, a main risk factor for coronary artery disease, emerged: liver- and thyroid hormone receptor isoform β-selective analogs. The present review will discuss the recent patents applied for sobetirome (GC-1), which set the course for the establishment of a novel approach to lower plasma cholesterol and triglycerides. We will focus on the major mechanisms conferring sobetirome lipid-lowering properties, including the induction of hepatic LDL receptor, the promotion of the so-called reverse cholesterol transport, and finally the induction of bile acid production and biliary sterol secretion. In summary, thyromimetics such as sobetirome may represent a useful treatment for combined hyperlipidemia, which is associated with a major cardiovascular risk.
Find related publications in this database (using NLM MeSH Indexing)
Acetates - therapeutic use
Animals -
Bile Acids and Salts - metabolism
Biological Markers - blood
Cholesterol - blood
Dyslipidemias - blood
Humans -
Hypolipidemic Agents - therapeutic use
Liver - drug effects
Molecular Mimicry -
Phenols - therapeutic use
Receptors, LDL - metabolism
Thyroid Hormones - metabolism
Treatment Outcome -
Triglycerides - blood

© Med Uni Graz • Impressum